New hope for patients whose nasopharyngeal cancer returns
NCT ID NCT07331428
Summary
This study is testing a new combination treatment for people whose nasopharyngeal cancer has returned in the original area after initial treatment. It will enroll 25 patients to receive an initial phase of two drugs (MRG003 and Tislelizumab) followed by a year of maintenance therapy with two other drugs. The main goal is to see how well the treatment shrinks or eliminates the cancer and how long patients live without their disease getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.